Illumina HiSeq 2000 paired end sequencing; Characterization of the difference of mRNA and lncRNA profiling between cisplatin-resistance and regular T24 bladder cancer cells
Characterization of the difference of mRNA and lncRNA profiling between cisplatin-resistance and regular T24 bladder cancer cells
T24 cells were obtained from American Type Culture Collection. To generate the cisplatin resistant cells, T24 were treated with a gradual increment (4, 8, 16, 32, 64 ug/ml cisplatin) with a discontinuous period until cells recover. 10^6 cells T24R and T24 cells were harvested for RNA-seq. 5 ug RNA was extracted by Trizol and treated with DNase I following the manufacturer's instructions. RNA quality was assessed using a Total RNA Nano chip with a 2100 Bioanalyzer instrument (Agilent). RNA-seq libraries were prepared from T24 cells using NEBNext Ultra II RNA library Prep Kit for Illumina (NEB,E7770S). Library quality was assessed using a DNA1000 chip with a 2100 Bioanalyzer instrument (Agilent).
Experimental Factor: phenotype
resistant to cisplatin